Suppr超能文献

吲达帕胺与安慰剂在执业医师治疗的高血压患者中的双盲比较。

Double-blind comparison of indapamide with a placebo in hypertensive patients treated by practicing physicians.

作者信息

Schaller M D, Waeber B, Brunner H R

出版信息

Clin Exp Hypertens A. 1985;7(7):985-94. doi: 10.3109/10641968509077243.

Abstract

The antihypertensive effect of indapamide (2.5 mg/day) was compared to that obtained with a placebo in a controlled trial carried out by 11 physicians in their private practice. Thirty-one patients with uncomplicated essential hypertension were included. After a run-in period of 3 weeks without any treatment, either indapamide (n = 16) or a placebo (n = 15) were administered for 8 weeks in double-blind fashion. Blood pressure decreased in both groups. In patients treated with indapamide, systolic pressure was significantly lower than in those given the placebo at 3 out of the 4 follow-up visits; diastolic pressure, however, was significantly lower only at the end of the trial. Both the active drug and the placebo were well tolerated. No significant change in body weight, plasma potassium and uric acid occurred during the study in either group of patients. It appears therefore that indapamide, at a dose which apparently has no major diuretic effect, may be useful for practitioners in managing patients with mild to moderate hypertension.

摘要

在一项由11位医生在其私人诊所开展的对照试验中,将吲达帕胺(2.5毫克/天)的降压效果与安慰剂的降压效果进行了比较。纳入了31例无并发症的原发性高血压患者。在为期3周的未进行任何治疗的导入期后,以双盲方式给予吲达帕胺(n = 16)或安慰剂(n = 15)治疗8周。两组患者的血压均下降。在接受吲达帕胺治疗的患者中,在4次随访中的3次,收缩压显著低于给予安慰剂的患者;然而,舒张压仅在试验结束时显著降低。活性药物和安慰剂的耐受性均良好。在研究期间,两组患者的体重、血钾和尿酸均无显著变化。因此,吲达帕胺在显然没有主要利尿作用的剂量下,可能对医生治疗轻度至中度高血压患者有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验